122 related articles for article (PubMed ID: 10693176)
1. Glucocorticoid blockade does not abrogate tumor-induced cachexia.
Rivadeneira DE; Naama HA; McCarter MD; Fujita J; Evoy D; Mackrell P; Daly JM
Nutr Cancer; 1999; 35(2):202-6. PubMed ID: 10693176
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.
Yasumoto K; Mukaida N; Harada A; Kuno K; Akiyama M; Nakashima E; Fujioka N; Mai M; Kasahara T; Fujimoto-Ouchi K
Cancer Res; 1995 Feb; 55(4):921-7. PubMed ID: 7850809
[TBL] [Abstract][Full Text] [Related]
3. [Role of NF-kappa B in cancer cachexia].
Zhou W; Jiang ZW; Jiang J; Li N; Li JS
Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):683-6. PubMed ID: 15329260
[TBL] [Abstract][Full Text] [Related]
4. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice.
Tanaka K; Urata N; Mikami M; Ogasawara M; Matsunaga T; Terashima N; Suzuki H
Inflamm Res; 2007 Jan; 56(1):17-23. PubMed ID: 17334666
[TBL] [Abstract][Full Text] [Related]
5. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
[TBL] [Abstract][Full Text] [Related]
6. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer.
Fujiki F; Mukaida N; Hirose K; Ishida H; Harada A; Ohno S; Bluethmann H; Kawakami M; Akiyama M; Sone S; Matsushima K
Cancer Res; 1997 Jan; 57(1):94-9. PubMed ID: 8988047
[TBL] [Abstract][Full Text] [Related]
7. Comparison of animal models for head and neck cancer cachexia.
Cannon T; Couch M; Yin X; Guttridge D; Lai V; Shores C
Laryngoscope; 2007 Dec; 117(12):2152-8. PubMed ID: 17921906
[TBL] [Abstract][Full Text] [Related]
8. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
9. Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma.
Matsumoto T; Fujimoto-Ouchi K; Tamura S; Tanaka Y; Ishitsuka H
Br J Cancer; 1999 Feb; 79(5-6):764-9. PubMed ID: 10070867
[TBL] [Abstract][Full Text] [Related]
10. [Cytokines in experimental cancer cachexia].
Niu Q; Li T; Liu A
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):382-4. PubMed ID: 11810767
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
Kanzaki M; Soda K; Gin PT; Kai T; Konishi F; Kawakami M
Cytokine; 2005 Dec; 32(5):234-9. PubMed ID: 16338141
[TBL] [Abstract][Full Text] [Related]
12. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
Strassmann G; Fong M; Freter CE; Windsor S; D'Alessandro F; Nordan RP
J Clin Invest; 1993 Nov; 92(5):2152-9. PubMed ID: 8227330
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor.
Strassmann G; Masui Y; Chizzonite R; Fong M
J Immunol; 1993 Mar; 150(6):2341-5. PubMed ID: 8450216
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Fujimoto-Ouchi K; Onuma E; Shirane M; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):807-15. PubMed ID: 17009035
[TBL] [Abstract][Full Text] [Related]
15. In vivo gene transfer of murine interleukin-4 inhibits colon-26-mediated cancer cachexia in mice.
Sturlan S; Beinhauer BG; Oberhuber G; Huang L; Aasen AO; Rogy MA
Anticancer Res; 2002; 22(5):2547-54. PubMed ID: 12529962
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
Kawamura I; Morishita R; Tomita N; Lacey E; Aketa M; Tsujimoto S; Manda T; Tomoi M; Kida I; Higaki J; Kaneda Y; Shimomura K; Ogihara T
Gene Ther; 1999 Jan; 6(1):91-7. PubMed ID: 10341880
[TBL] [Abstract][Full Text] [Related]
17. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice.
Kawamura I; Lacey E; Yamamoto N; Sakai F; Takeshita S; Inami M; Nishigaki F; Naoe Y; Tsujimoto S; Manda T; Shimomura K; Goto T
Anticancer Res; 1999; 19(5B):4105-11. PubMed ID: 10628361
[TBL] [Abstract][Full Text] [Related]
18. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.
Cahlin C; Körner A; Axelsson H; Wang W; Lundholm K; Svanberg E
Cancer Res; 2000 Oct; 60(19):5488-93. PubMed ID: 11034092
[TBL] [Abstract][Full Text] [Related]
19. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
Gelin J; Moldawer LL; Lönnroth C; Sherry B; Chizzonite R; Lundholm K
Cancer Res; 1991 Jan; 51(1):415-21. PubMed ID: 1703040
[TBL] [Abstract][Full Text] [Related]
20. Murine interleukin-12 prevents the development of cancer cachexia in a murine model.
Mori K; Fujimoto-Ouchi K; Ishikawa T; Sekiguchi F; Ishitsuka H; Tanaka Y
Int J Cancer; 1996 Sep; 67(6):849-55. PubMed ID: 8824558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
